Using alendronate to treat osteonecrosis in adults with sickle cell disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to evaluate the safety and preliminary efficacy of oral alendronate in adults with sickle cell disease (SCD) who have osteonecrosis. Participants will receive a weekly dose of alendronate for 24 weeks, and their pain levels and bone health will be monitored through various assessments, including the ASCQ-Me Pain Impact scores and bone biomarkers. The study will recruit 24 adults from the University of California Davis Medical Center, with the goal of understanding how well they tolerate the medication and any improvements in their condition over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
* Ability to provide written informed consent
* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
* Negative urine pregnancy test for anyone of childbearing potential at study entry

Exclusion Criteria:

* Pregnant women
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Prisoners
* Hospitalizations (for any cause) within 2 weeks of study entry

Where it's running

• UC Davis Comprehensive Cancer Center
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Oyebimpe O Adesina, MD, MS — UC Davis School of Medicine
• Study coordinator: Leyla Y Teos, PhD
• Email: lyteos@health.ucdavis.edu
• Phone: (916) 460-2749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Checking measles vaccine response in children with sickle cell disease

  This study tests whether infants and young children with sickle cell disease develop enough protection in the weeks after their measles vaccine.

  Recruiting at 3 sites Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio and 2 other locations · NCT07356050

• Senicapoc for Sickle Cell Disease with Hemolytic Phenotype

  A mid-stage study tests whether daily senicapoc helps people with sickle cell disease who have ongoing red blood cell breakdown and low hemoglobin, despite hydroxyurea, by comparing it to a placebo over 24 weeks.

  Recruiting at 4 sites Phase 2 Biossil Inc. · Toronto, Ontario and 3 other locations · NCT07282210

• Evaluating a single dose of CTX001 for treating transfusion-dependent beta-thalassemia and severe sickle cell disease

  This study is testing a single dose of a new treatment called CTX001 to see if it can help people with transfusion-dependent beta-thalassemia or severe sickle cell disease feel better.

  Recruiting at 6 sites Phase 3 Vertex Pharmaceuticals Incorporated · New York, New York and 5 other locations · NCT05477563

• Haploidentical stem cell transplantation for sickle cell disease

  This study is testing a new type of stem cell transplant for people with sickle cell disease to see if it can cure the disease while causing fewer complications.

  Recruiting at 4 sites Phase 2 University of Regensburg · Vienna and 8 other locations · NCT04201210

• Understanding hydroxyurea effects during pregnancy and breastfeeding in women with sickle cell disease

  This study looks at how taking hydroxyurea during pregnancy and breastfeeding affects women with sickle cell disease and their babies to better understand the risks and outcomes.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT04093986

• Collecting blood samples to study sickle cell disease

  This study is collecting blood samples from healthy people and those with sickle cell disease to see if new drugs can help stop red blood cells from sickling.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00542230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.